Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status

Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status

Abstract Carboplatin plus etoposide is a standard treatment for older extensive‐stage small‐cell lung cancer (ES‐SCLC) patients with performance status (PS) 2. However, older patients often exhibit poor PS (3, 4), and the treatment effect in them is poorly understood. To determine the therapeutic ef...

Full description

Bibliographic Details
Main Authors: Nobuaki Mamesaya, Hiroaki Kodama, Yuko Iida, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Tetsuo Shimizu, Yasuhiro Gon, Toshiaki Takahashi
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Thoracic Cancer
Subjects:
aged
carboplatin
etoposide
performance status
small‐cell lung cancer
Online Access:https://doi.org/10.1111/1759-7714.14811

Internet

https://doi.org/10.1111/1759-7714.14811

Similar Items